| John A Kao, MD | |
|
98-1079 Moanalua Road Suite 680, Honolulu, HI 96701 | |
| (808) 485-4553 | |
| (808) 485-4447 |
| Full Name | John A Kao |
|---|---|
| Gender | Male |
| Speciality | Cardiovascular Disease (cardiology) |
| Experience | 28 Years |
| Location | 98-1079 Moanalua Road Suite 680, Honolulu, Hawaii |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1336187517 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RC0000X | Internal Medicine - Cardiovascular Disease | 15397 (Hawaii) | Secondary |
| 207RI0011X | Internal Medicine - Interventional Cardiology | 15397 (Hawaii) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Pali Momi Medical Center | Aiea, HI | Hospital |
| The Queens Medical Center | Honolulu, HI | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Pali Momi Medical Center | 6406746916 | 60 |
News Archive
Numerous novel oncology agents are currently in phase I monotherapy trials. New Medicine's Oncology KnowledgeBASE (nm|OK) has updated the records of 92 such agents with preclinical or clinical results reported during the 2005 meetings of the American Association for Cancer Research (AACR)
Novavax, Inc. reported today that its trivalent seasonal influenza virus-like-particle (VLP)-based vaccine candidate was safe and immunogenic against the 2009-2010 seasonal influenza virus strains in older adults 60 years or higher in age.
Researchers from the University of Pennsylvania School of Medicine have found that inhibitors of an enzyme called cathepsin L prevent the SARS (severe acute respiratory syndrome) virus from entering target cells. SARS is caused by an emergent coronavirus. There is no effective treatment at this time.
Teva Pharmaceutical Industries Ltd. has announced that the U.S. Food and Drug Administration has granted final approval for the Company's ANDA for Flumazenil Injection, 0.1 mg/mL. Commercial marketing of this product will begin immediately.
Santen EMEA and NTC are delighted to announce that the results of their phase III clinical study, LEADER7, have been published in Eye.
› Verified 3 days ago
| Entity Name | Straub Clinic & Hospital |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1457306508 PECOS PAC ID: 6305759754 Enrollment ID: O20031111000417 |
News Archive
Numerous novel oncology agents are currently in phase I monotherapy trials. New Medicine's Oncology KnowledgeBASE (nm|OK) has updated the records of 92 such agents with preclinical or clinical results reported during the 2005 meetings of the American Association for Cancer Research (AACR)
Novavax, Inc. reported today that its trivalent seasonal influenza virus-like-particle (VLP)-based vaccine candidate was safe and immunogenic against the 2009-2010 seasonal influenza virus strains in older adults 60 years or higher in age.
Researchers from the University of Pennsylvania School of Medicine have found that inhibitors of an enzyme called cathepsin L prevent the SARS (severe acute respiratory syndrome) virus from entering target cells. SARS is caused by an emergent coronavirus. There is no effective treatment at this time.
Teva Pharmaceutical Industries Ltd. has announced that the U.S. Food and Drug Administration has granted final approval for the Company's ANDA for Flumazenil Injection, 0.1 mg/mL. Commercial marketing of this product will begin immediately.
Santen EMEA and NTC are delighted to announce that the results of their phase III clinical study, LEADER7, have been published in Eye.
› Verified 3 days ago
| Entity Name | Pali Momi Medical Center |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1275588329 PECOS PAC ID: 6406746916 Enrollment ID: O20040318000395 |
News Archive
Numerous novel oncology agents are currently in phase I monotherapy trials. New Medicine's Oncology KnowledgeBASE (nm|OK) has updated the records of 92 such agents with preclinical or clinical results reported during the 2005 meetings of the American Association for Cancer Research (AACR)
Novavax, Inc. reported today that its trivalent seasonal influenza virus-like-particle (VLP)-based vaccine candidate was safe and immunogenic against the 2009-2010 seasonal influenza virus strains in older adults 60 years or higher in age.
Researchers from the University of Pennsylvania School of Medicine have found that inhibitors of an enzyme called cathepsin L prevent the SARS (severe acute respiratory syndrome) virus from entering target cells. SARS is caused by an emergent coronavirus. There is no effective treatment at this time.
Teva Pharmaceutical Industries Ltd. has announced that the U.S. Food and Drug Administration has granted final approval for the Company's ANDA for Flumazenil Injection, 0.1 mg/mL. Commercial marketing of this product will begin immediately.
Santen EMEA and NTC are delighted to announce that the results of their phase III clinical study, LEADER7, have been published in Eye.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| John A Kao, MD 98-1079 Moanalua Road Suite 680, Honolulu, HI 96701 Ph: (808) 485-4553 | John A Kao, MD 98-1079 Moanalua Road Suite 680, Honolulu, HI 96701 Ph: (808) 485-4553 |
News Archive
Numerous novel oncology agents are currently in phase I monotherapy trials. New Medicine's Oncology KnowledgeBASE (nm|OK) has updated the records of 92 such agents with preclinical or clinical results reported during the 2005 meetings of the American Association for Cancer Research (AACR)
Novavax, Inc. reported today that its trivalent seasonal influenza virus-like-particle (VLP)-based vaccine candidate was safe and immunogenic against the 2009-2010 seasonal influenza virus strains in older adults 60 years or higher in age.
Researchers from the University of Pennsylvania School of Medicine have found that inhibitors of an enzyme called cathepsin L prevent the SARS (severe acute respiratory syndrome) virus from entering target cells. SARS is caused by an emergent coronavirus. There is no effective treatment at this time.
Teva Pharmaceutical Industries Ltd. has announced that the U.S. Food and Drug Administration has granted final approval for the Company's ANDA for Flumazenil Injection, 0.1 mg/mL. Commercial marketing of this product will begin immediately.
Santen EMEA and NTC are delighted to announce that the results of their phase III clinical study, LEADER7, have been published in Eye.
› Verified 3 days ago
Dr. Isac C. Thomas, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 3288 Moanalua Rd, Honolulu, HI 96819 Phone: 808-432-0000 | |
Nishal Brahmbhatt, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 1301 Punchbowl St, Honolulu, HI 96813 Phone: 808-691-1000 | |
Dr. Thomas Jon Uyehara Wong, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 1301 Punchbowl St, Honolulu, HI 96813 Phone: 808-691-1000 | |
Taryn Kikue Miyake, MD Internal Medicine Medicare: Not Enrolled in Medicare Practice Location: 1356 Lusitana St Fl 7, Honolulu, HI 96813 Phone: 808-586-2910 | |
Joshua Bruce Taylor, MD Internal Medicine Medicare: Not Enrolled in Medicare Practice Location: 1356 Lusitana St Fl 7, Honolulu, HI 96813 Phone: 520-909-7445 | |
Raja Haris Rizwan, MD Internal Medicine Medicare: Not Enrolled in Medicare Practice Location: 1356 Lusitana St Fl 7, Honolulu, HI 96813 Phone: 808-392-3286 | |
Dr. Elizabeth G Quinn, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 1010 Pensacola St, Honolulu, HI 96814 Phone: 808-432-2303 |